Oncology Drugs Market Is Expected to Grow at A CAGR of 12.7% Over the Forecast Period Owing to Rising Number of Pipeline Cell-Therapy Products, Says Absolute Markets Insights
PUNE, India, Sept. 10, 2019 /PRNewswire/ -- In the recent past, the FDA approved cell therapies to treat CD19-positive hematological cancers. This have in turn encouraged research institutes to indulge themselves in substantial Research & Development to innovate more number of cell therapies associated with Cancer. Such a factor is expected to aid the global oncology drugs market over the forecast period. However, side-effects associated with these drugs has critically impacted the global industry growth in recent years. The global cancer cell therapy pipeline includes 1,011 active agents. Amongst them, the chimeric antigen receptor (CAR)-T cell therapy number has increased substantially and is cumulating to a total of 568 agents. Such a trend is expected to propel the overall oncology drug market growth in future years.
https://mma.prnewswire.com/media/831667/Absolute_Market_Insights_Logo.jpg
Request for Sample Copy@
https://www.absolutemarketsinsights.com/request_sample.php?id=273
The detailed research study provides qualitative and quantitative analysis of the global oncology drugs market. The market has been analyzed from demand as well as supply side. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
Key Findings of the Report:
-- In terms of revenue, global oncology drugs market was valued at US$ 119
billion in 2018. The introduction and approval of anti-PD-1 agents'
nivolumab and pembrolizumab for NSCLC has bought a new era for the
cancer industry.
-- The number of patients receiving single-agent chemotherapy decreased
considerably in the recent past and the patients who received EGFR-TKI
based therapy also reduced substantially
-- Single drug therapies coupled with monoclonal antibodies against
programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have
shown little efficacy in patients suffering from metastatic breast
cancer. The same is low number of tumour-infiltrating lymphocytes, found
in most of the breast cancers. As a result, the development of
combinations of molecularly targeted therapies and immunotherapy have
proven to be a great success.
-- The China and United States hold the leading positions in the cancer
cell therapy pipeline. The number for the same are 439 and 305 agents
respectively. Majority of the drugs developed in the United States are
at pre-clinical stage, whereas the drugs that are being developed in
China are at clinical stages
-- Some of the industry participants present in the oncology drugs market
are F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Eli
Lilly and Company, Novartis AG, Pfizer Inc., Bayer AG, AstraZeneca,
Merck & Co., Inc.,CELGENE CORPORATION and Polaris Pharmaceuticals
amongst others
-- In August, 2019, the U.S. FDA granted approval to Rozlytrek. This drug
is for adoslescents and adult who are suffering from genetic cancer
defects. This drug got approval for treating diseases like NTRK
(neurotrophic tyrosine receptor kinase) gene fusion. The drug has a
unique ability to shrink tumors and has been evaluated in four clinical
trials, studying the adults who are suffering from NTRK fusion-positive
tumors.
Enquiry Before Buying@
https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=273
-- Oncology drugs market By Indication
-- Breast Cancer
-- Prostate Cancer
-- Basal Cell Cancer
-- Skin Cancer (Non-Melanoma)
-- Colorectal cancer
-- Lung Cancer
-- Renal Cancer
-- Bladder Cancer
-- Lymphoma
-- Others
-- Oncology drugs market By Treatment
-- Drug Therapies
-- Antimetabolites
-- Antitumor Antibiotics
-- Asparagine-Specific Enzymes
-- Bisphosphonates & Biosimilars
-- DNA-Damaging Agents (Antineoplastics) and Alkylating Agents
-- Inhibitors
-- DNA-Repair Enzyme Inhibitors
-- Histone Deacetylase Inhibitors
-- Janus-Associated Kinase (JAK) Inhibitors
-- Phosphoinositide 3-kinase inhibitors (PI3K inhibitors)
-- Proteasome Inhibitors
-- Tyrosine Kinase Inhibitors
-- PD-1 and PD-L1 inhibitorsOthers
-- Monoclonal Antibodies
-- Others
-- Surgery
-- Open Surgery
-- Minimally Invasive Surgery
-- Radiation Therapy
-- Chemotherapy
-- Immunotherapy
-- Chimeric antigen receptor (CAR) T-cell therapy
-- Cytokine Treatment
-- Donor lymphocyte infusion
-- Monoclonal Antibody Treatment
-- Others
-- Targeted Therapy
-- Hormone Therapy
-- Stem Cell Transplant
-- Autologous stem cell transplantation
-- Allogeneic stem cell transplantation
-- Reduced-Intensity Allogeneic Stem Cell Transplantation
-- Graft-Versus-Host Disease
-- Precision Medicine
-- Others
-- By Geography
-- North America
-- U.S.
-- Canada
-- Mexico
-- Rest of North America
-- Europe
-- France
-- The UK
-- Spain
-- Germany
-- Italy
-- Nordic Countries
-- Denmark
-- Finland
-- Iceland
-- Norway
-- Sweden
-- Benelux Union
-- Belgium
-- The Netherlands
-- Luxemburg
-- Rest of Europe
-- Asia Pacific
-- China
-- Japan
-- India
-- New Zealand
-- Australia
-- South Korea
-- Southeast Asia
-- Indonesia
-- Thailand
-- Malaysia
-- Singapore
-- Rest of Southeast Asia
-- Rest of Asia Pacific
-- Middle East & Africa
-- Saudi Arabia
-- UAE
-- Egypt
-- Kuwait
-- South Africa
-- Rest of Middle East & Africa
-- Latin America
-- Brazil
-- Argentina
-- Rest of Latin America
Purchase the Premium Report@
https://www.absolutemarketsinsights.com/checkout?id=273
About Us:
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.
From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.
Contact Us:
Company: Absolute Markets Insights
Email id: sales@absolutemarketsinsights.com
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
The Work Lab,
Model Colony, Shivajinagar, Pune, MH, 411016
Website: https://www.absolutemarketsinsights.com/
Follow Us on Social Media:
https://www.facebook.com/AbsoluteMarketsInsights/
https://twitter.com/AbsoluteMI
https://www.linkedin.com/company/absolute-markets-insights/
https://plus.google.com/117657938830005040584
SOURCE Absolute Markets Insights
